MDS-EB Clinical Trial - Allogenic NK Cell Transfusion Azacitidine MDS-EB

See also
	Status	Clinical Trial	Phase
	Terminated	`NCT05933070` - A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML	Phase 1
	Recruiting	`NCT04216355` - Low-dose AZA Combined With Short Term CAG Derived Regimen as a Bridging Treatment in Patients With Advanced MDS Prior to Allo-HSCT	Phase 2/Phase 3

See also

Status

Clinical Trial

Phase

Terminated

NCT05933070 - A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML

Phase 1

Recruiting

NCT04216355 - Low-dose AZA Combined With Short Term CAG Derived Regimen as a Bridging Treatment in Patients With Advanced MDS Prior to Allo-HSCT

Phase 2/Phase 3

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT04599426
Study type	Interventional
Source	The Second Hospital of Shandong University
Contact	Chengyun Zheng, Ph.D.
Phone	+86-531-85875502
Email	chengyun.zheng@ki.se
Status	Not yet recruiting
Phase	Phase 1/Phase 2
Start date	December 1, 2020
Completion date	December 30, 2023

Allogenic NK Cell Transfusion Azacitidine MDS-EB

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms